Report Publication Announcement • May 16, 2022
Report Publication Announcement
Open in ViewerOpens in native device viewer
Bergen, Norway, 16 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the ABG Sundal Collier Life Science Summit taking place on Wednesday 18 May at 11:30 CEST.
The presentation slides will be made available on the Company's website in the Investors section shortly after the presentation.
-Ends-
Martin Olin CEO, BerGenBio ASA [email protected]
Rune Skeie, CFO, BerGenBio ASA [email protected] +47 917 86 513
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone Consilium Strategic Communications [email protected] +44 20 3709 5700
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.